Research‑Grade mRNA That Moves as Fast as Your Ideas Learn more about key considerations when sourcing research-grade mRNA and discover Vernal’s approach to its new research-grade mRNA manufacturing service offering. Read Article Unlocking Oral RNA Therapeutics: Overcoming Barriers to Gut-Stable…
Messenger RNA (mRNA) has become a workhorse of vaccine and therapeutic discovery, but its pace is unforgiving. Project teams now need dozens of constructs, with different sequences, cap analogs, nucleoside mixes, and/or UTR, delivered in weeks, not months. They also…
Advancements in Biopharma Spur Innovation Christian Cobaugh, chief scientific officer and founder of Vernal Biosciences, offered PharmaTech editor Susan Haigney comments about where he believes mRNA and LNP advancements fit into the biopharm innovation landscape. Source: Pharmaceutical Technology, June 2025,…
Well-Defined mRNA Platform Processes & Collaboration Advanced a Novel Gene Therapy in Jeopardy Learn how Vernal Bio changed the course of a stalled cancer gene therapy program, pairing proven mRNA platform methods with scientific flexibility and hands-on collaboration. Innovator’s Challenges…
Awakening the Giant: The Next Frontier in mRNA Therapeutics We’ve seen what mRNA can do in vaccines—but that was only the beginning. In a new article published in American Pharmaceutical Review , Vernal’s CSO Christian Cobaugh, Ph.D., outlines how mRNA…
Messenger RNA has redefined what rapid looks like in drug development. Yet the very flexibility that makes mRNA attractive also makes it unforgiving—minute variations in purity, structure, or LNP encapsulation can eliminate potency or introduce safety risks. It’s never too soon to…
The remarkable success of messenger RNA-based vaccines during the COVID-19 pandemic has sparked widespread interest and enthusiasm around mRNA technology. But vaccines are just the beginning. Researchers and biotech innovators worldwide are rapidly uncovering the broader potential of mRNA to…
The Evolving Needs of Therapeutic mRNA Developers Insights on the next wave of challenges mRNA innovators face as an increasing number of therapeutics move through the pipeline. Read Article Behind the Headlines Panel Discussion Christian Cobaugh, Ph.D., Vernal Biosciences founder…
How Vernal Helped Akagera Boost Vaccine Efficacy, Cut Costs, and Speed Development Pioneering mRNA Therapies for Infectious Diseases in Cost-Sensitive Regions Founded in 2019, Akagera Medicines is advancing novel liposomal formulations of antibacterial drugs to enhance drug delivery and uptake…
Given the strides medical researchers and therapeutic developers were making, the possibility of commercializing mRNA therapeutics began looking bright about ten to fifteen years ago. However, one of the most pressing issues restricting researchers’ efforts was the lack of a…
How an mRNA-encoded antibody platform could accelerate therapies to clinic Therapeutic antibody production is traditionally complex and costly, which drives up treatment prices. However, encoding antibodies with mRNA offers a potential solution to many of these challenges, making the process…
mRNA for Antibody Manufacturing In collaboration, Charles River Lab and Vernal Biosciences released this scientific poster. Since its release, new advancements have been made and new data is available to share. Join the webinar on December 12 to dive into…